Journal
PSYCHONEUROENDOCRINOLOGY
Volume 38, Issue 9, Pages 1729-1737Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.psyneuen.2013.02.006
Keywords
IGF-I; IGFBP-3; Insulin; Cerebrospinal fluid; Alzheimer's disease; Mild cognitive impairment; AD biomarker
Categories
Funding
- Swedish Research Council
- Swedish Foundation for Strategic Research
- ALF/LUA Research grant in Gothenburg
- Lundberg Foundation
- Torsten and Ragnar Soderberg's Foundation
- Lundbeck Foundation
- Sahlgrenska University Hospital
- Sahlgrenska Academy
- Stiftelsen Psykiatriska Forskningsfonden
- Stiftelsen Gamla Tjanarinnor
- Uppsala Universitets Medicinska Fakultet stiftelse for psykiatrisk och neurologisk forskning
- Alzheimer Foundation, Sweden
- Dementia Association, Sweden
Ask authors/readers for more resources
Background: Although insulin-like growth factor-I (IGF-I) is of importance for the adult function of the central nervous system (CNS), little is known of the significance of IGF-I in cerebrospinal fluid (CSF) in relation to Alzheimer's disease (AD). Methods: A cross-sectional study of 60 consecutive patients under primary evaluation of cognitive impairment and 20 healthy controls. The patients had AD dementia or mild cognitive impairment (MCI) diagnosed with AD dementia upon follow-up (n = 32), stable MCI (SMCI, n = 13), or other dementias (n = 15). IGF-I, IGF-binding protein-3 (IGFBP-3), and insulin were measured in serum and CSF. Results: Serum IGF-I level was increased in AD patients and in patients with other dementias compared to healthy controls (P = 0.01 and P < 0.05, respectively). Serum IGFBP-3 concentration was increased in AD and SMCI patients compared to controls (P = 0.001 and P < 0.05, respectively). CSF levels of IGF-I and IGFBP-3 as well as serum and CSF levels of insulin were similar in all study groups. In the total study population (n = 80), serum levels of IGF-I and IGFBP-3 correlated negatively with CSF beta-amyloid(1-42) (A beta(1-42)) level (r = -0.29, P = 0.01 and r = -0.27, P = 0.02, respectively) and in the AD patients (n = 32), the increased CSF/serum IGF-I ratio correlated positively with the CSF level of phosphorylated tau protein (P-tau; r = 0.42, P = 0.02). Conclusion: Patients with AD as well as other dementias had high levels of IGF-I in serum but not in CSF. In AD patients, the IGF-I system was associated with biomarkers of AD disease status. (C) 2013 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available